Development of a method for the determination of caffeine anhydrate in various designed intact tables by near-infrared spectroscopy: A comparison between reflectance and transmittance technique

Journal of Pharmaceutical and Biomedical Analysis

Volumn 47, Issue 4-5, 2008, Pages 819-827

  Ito, Masatomo ^a   Suzuki, Tatsuya ^a   Yada, Shuichi ^a   Kusai, Akira ^a   Nakagami, Hiroaki ^a   Yonemochi, Etsuo ^b   Terada, Katsuhide ^b  

^a DAIICHI SANKYO CO   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Caffeine anhydrate; Partial least squares; Reflectance near infrared spectroscopy; Tablet design; Transmittance near infrared spectroscopy

Indexed keywords

CAFFEINE;

ANALYTICAL ERROR; ARTICLE; CALIBRATION; DRUG DESIGN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; MODEL; NEAR INFRARED SPECTROSCOPY; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; REFLECTANCE NEAR INFRARED SPECTROSCOPY; TABLET COMPRESSION; TABLET PROPERTY; TABLET THICKNESS; TRANSMITTANCE NEAR INFRARED SPECTROSCOPY;

BIOLOGICAL ASSAY; CAFFEINE; CALIBRATION; CENTRAL NERVOUS SYSTEM STIMULANTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPRESSIVE STRENGTH; DOSAGE FORMS; LEAST-SQUARES ANALYSIS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; REGRESSION ANALYSIS; SPECTROSCOPY, NEAR-INFRARED; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 44749087710     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.03.033     Document Type: Article

References (39)

1. Food, and Drug Administration. Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004)
2. Rantanen J., Lehtola S., Rämet P., Mannermaa J.P., and Yliruusi J. Powder Technol. 99 (1998) 163-170
3. Rantanen J., Rasanen E., Tenhunen J., Kansakoski M., Mannermaa J., and Yliruusi J. Eur. J. Pharm. Biopharm. 50 (2000) 271-276
4. Jorgensen A., Rantanen J., Karjalainen M., Khriachtchev L., Rasanen E., and Yliruusi J. Pharm. Res. 19 (2002) 1285-1291
5. Jorgensen A.C., Luukkonen P., Rantanen J., Schaefer T., Juppo A.M., and Yliruusi J. J. Pharm. Sci. 93 (2004) 2232-2243
6. Davis T.D., Peck G.E., Stowell J.G., Morris K.R., and Byrn S.R. Pharm. Res. 21 (2004) 860-866
7. Findlay W.P., Peck G.R., and Morris K.R. J. Pharm. Sci. 94 (2005) 604-612
8. Gupta A., Peck G.E., Miller R.W., and Morris K.R. J. Pharm. Sci. 93 (2004) 1047-1053
9. Gupta A., Peck G.E., Miller R.W., and Morris K.R. J. Pharm. Sci. 94 (2005) 1589-1597
10. Wargo D.J., and Drennen J.K. J. Pharm. Biomed. Anal. 14 (1996) 1415-1423
11. Sekulic S.S., Wakeman J., Doherty P., and Hailey P.A. J. Pharm. Biomed. Anal. 17 (1998) 1285-1309
12. El-Hagrasy A.S., Morris H.R., D'Amico F., Lodder R.A., and Drennen III J.K. J. Pharm. Sci. 90 (2001) 1298-1307
13. El-Hagrasy A.S., D'Amico F., and Drennen III J.K. J. Pharm. Sci. 95 (2006) 392-406
14. El-Hagrasy A.S., Delgado-Lopez M., and Drennen III J.K. J. Pharm. Sci. 95 (2006) 407-421
15. El-Hagrasy A.S., and Drennen J.K. J. Pharm. Sci. 95 (2006) 422-434
16. Berntsson O., Danielsson L.G., Lagerholm B., and Folestad S. Powder Technol. 123 (2002) 185-193
17. Li W., Johnson M.C., Bruce R., Ulrich S., Rasmussen H., and Worosila G.D. Int. J. Pharm. 326 (2006) 182-185
18. Li W., Johnson M.C., Bruce R., Rasmussen H., and Worosila G.D. J. Pharm. Biomed. Anal. 43 (2007) 711-717
19. Duong N.H., Arratia P., Muzzio F., Lange A., Timmermans J., and Reynolds S. Drug Dev. Ind. Pharm. 29 (2003) 679-687
20. Arratia P.E., Duong N., Muzzio F.J., Godbole P., Lange A., and Reynolds S. Powder Technol. 161 (2006) 202-208
21. El-Hagrasy A.S., Chang S.Y., and Kiang S. Pharm. Dev. Technol. 11 (2006) 303-312
22. Morisseau K.M., and Rhodes C.T. Pharm. Res. 14 (1997) 108-111
23. Perez-Ramos J.D., Findlay W.P., Peck G., and Morris K.R. AAPS PharmSciTech 6 (2005) E127-E136
24. Roggo Y., Jent N., Edmond A., Chalus P., and Ulmschneider M. Eur. J. Pharm. Biopharm. 61 (2005) 100-110
25. Ritchie G.E., Roller R.W., Ciurczak E.W., Mark H., Tso C., and MacDonald S.A. J. Pharm. Biomed. Anal. 29 (2002) 159-171
26. Laasonen M., Harmia-Pulkkinen T., Simard C., Rasanen M., and Vuorela H. Anal. Chem. 75 (2003) 754-760
27. Blanco M., Alcala M., Gonzalez J.M., and Torras E. J. Pharm. Sci. 95 (2006) 2137-2144
28. Blanco M., and Alcala M. Anal. Chim. Acta 557 (2006) 353-359
29. Meza C.P., Santos M.A., and Romanach R.J. AAPS PharmSciTech 7 (2006) E1-E9
30. Weiβner B.V., Henck J.-O., and Reich G. Proceedings of the Fifth World Meeting on Pharmaceutics. Biopharmaceutics and Pharmaceutical Technology (2006)
31. Li W., Bashai-Woldu A., Ballard J., Johnson M., Agresta M., Rasmussen H., Hu S., Cunningham J., and Winstead D. Int. J. Pharm. 340 (2007) 97-103
32. Mueller R., and Kleinebudde P. Eur. J. Pharm. Biopharm. 64 (2006) 388-392
33. Mueller R., and Kleinebudde P. Eur. J. Pharm. Biopharm. 67 (2007) 458-463
34. Tsuchikawa S., and Tsutsumi S. Proceedings of the 9th International Conference on Near Infrared Spectroscopy (2000) 89-94
35. Tsuchikawa S. In: Tsuchikawa S. (Ed). Useful and Advanced Information in the Field of Near Infrared Spectroscopy (2003), Research Signpost, Trivandrum 293-307
36. Gottfries J., Depui H., Fransson M., Jongeneelen M., Josefson M., Langkilde F.W., and Witte D.T. J. Pharm. Biomed. Anal. 14 (1996) 1495-1503
37. Thosar S.S., Forbess R.A., Ebube N.K., Chen Y., Rubinovitz R.L., Kemper M.S., Reier G.E., Wheatley T.A., and Shukla A.J. Pharm. Dev. Technol. 6 (2001) 19-29
38. Iyer M., Morris H.R., and Drennen III J.K. J. Near Infrared Spectrosc. 10 (2002) 233-245
39. The European Agency for the Evaluation of Medicinal Products, Note for Guidance on the Use pf Near Infrared Spectroscopy by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations, 2003.